Navigation Links
Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
Date:5/5/2008

HOPKINTON, Mass., May 5 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will participate in a panel entitled "Traumatic Brain and Spinal Cord Injury" at the Neurotech Industry Investing & Partnering Conference in Boston, MA, Thursday, May 8, 2008. The session will focus on emerging treatments of major traumatic injuries to the Central Nervous System (CNS). The event is the premier partnering and investing conference for the segment of the healthcare sector focused on neurological technologies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

About Alseres

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's focus is reflected in several important initiatives. CETHRIN, a recombinant- protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Alseres is a trademark and CETHRIN and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or

Adam Friedman -- 212-981-2529 ext 18 adam@adam-friedman.com

http://www.alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
4. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
5. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
6. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Barr Pharmaceuticals, Inc. Executive Bios
11. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... ... The International Essential Tremor Foundation (IETF) will host a free educational forum ... will take place on Saturday, Aug. 26 at the Embassy Suites by Hilton Cleveland ... 9 a.m. to 12 p.m., with check-in beginning at 8 a.m. The event is ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, ... awareness for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... of long term skin conditions, including cancer. In the short term, overexposure ...
(Date:7/24/2017)... Beach, California (PRWEB) , ... July 24, 2017 ... ... commercialization of autologous fat (adipose) transfer systems announces the issuance of United States ... ‘324 patent) for its adipose filtration technology. The '398 and '324 patents ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Sharon Kleyne, host ... and Your Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the ... of myopia in China. , The article by Zidor Aldama described the situation in ...
(Date:7/24/2017)... Calif. (PRWEB) , ... July 24, 2017 , ... A ... from food addiction to sexual abuse, and how she has overcome them. “Forbidden Memories: ... instances in her life and how she has risen above. , In “Memories,” readers ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)...  Endo International plc (NASDAQ: ENDP ) ... its manufacturing network, the Company will be ceasing operations ... Huntsville, Alabama . The closure of the ... 12 to 18 months. The Huntsville ... commoditized products and these restructuring actions are intended to ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
(Date:7/13/2017)... -- Centurion Medical Products, a leader in medical product innovation and global ... device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a hospice,s ... while preventing unneeded emergency department admission due to severe fecal impaction. ...
Breaking Medicine Technology: